

# The influence of redox activity of inhaled nano-sized cerium dioxide on respiratory, immune and cardiovascular effects in multiple mouse models

**Authors:** Susan Dekkers<sup>1\*</sup>, Mark Miller<sup>2</sup>, Roel Schins<sup>3</sup>, Rob Vandebriel<sup>1</sup>, Isabella Römer<sup>4</sup>, Mike Russ<sup>5</sup>, Marie-France Belinga-Desaunay-Nault<sup>4</sup>, Shea Connell<sup>2</sup>, Ian Smith<sup>2</sup>, Paul Fokkens<sup>1</sup>, John Boere<sup>1</sup>, Daan Leseman<sup>1</sup>, Jolanda Vermeulen<sup>1</sup>, Eric Gremmer<sup>1</sup>, Liset de la Fonteyne<sup>1</sup>, Harm Heusinkveld<sup>1,3</sup>, Catrin Albrecht<sup>3</sup>, Tina Wahle<sup>3</sup>, Adriana Sofranko<sup>3</sup>, Christine Sopotan<sup>6</sup>, Wim de Jong<sup>1</sup>, Flemming Cassee<sup>1,6,7</sup>

- 1 RIVM, The Netherlands,
- 2 University of Edinburgh, United Kingdom,
- 3 IUF, Germany,
- 4 University of Birmingham, United Kingdom,
- 5 Promethean Particles Ltd, United Kingdom,
- 6 Institute for Translational Vaccinology (Intravacc), The Netherlands,
- 7 University of Utrecht, The Netherlands.

\*Susan.Dekkers@RIVM.nl

## Conclusions

- Inhalation of CeO<sub>2</sub> NPs caused minimal toxicological effects.
- Redox modification via ZrO<sub>2</sub>-doping has limited effect on these responses.
- Further studies with nanomaterials of greater inherent toxicity or a wider range of redox activities are needed to fully assess the influence of redox activity on the toxicity of nanomaterials.

## Results

CeO<sub>2</sub> NPs caused modest inflammatory lesions in the lung (increased incidence in minimal chronic inflammation, alveolar inflammation and alveolar macrophages), which were not related to the % of ZrO<sub>2</sub>-doping.

CeO<sub>2</sub> NPs did not alter the size of atherosclerotic plaques in the brachiocephalic arteries of the ApoE<sup>-/-</sup> mice, although there was a trend towards an increased inflammatory cell content in plaques with increasing ZrO<sub>2</sub>-doping of the NPs (see Figure 2). Heavily inflamed plaques in humans are vulnerable to rupture, that can trigger a cardiovascular event, e.g. heart attack.

## Introduction

For a successful safe by design approach and safety evaluation, knowledge on the influence of the physicochemical characteristics of nanomaterials on their toxic potential and the underlying biological mechanisms of action is needed. We assessed the influence of redox activity by modification of cerium dioxide nanoparticles (CeO<sub>2</sub> NPs) via zirconium dioxide (ZrO<sub>2</sub>) doping on respiratory, immune and cardiovascular effects in mice following subacute inhalation.

## Materials and methods

- Animals: Healthy C57BL/6J, Western-diet fed ApoE<sup>-/-</sup> (Apolipoprotein E knockout mice, prone to the development of atherosclerotic plaques) and ovalbumin (OVA) sensitised BALB/c mice.
- Exposure: 4 weeks to clean air or CeO<sub>2</sub> NPs with 0%, 22% or 78% ZrO<sub>2</sub>-doping (4 mg/m<sup>3</sup>, 3 hours/day, 5 days/week).
- Effects: assessed 2 or 4 weeks after exposure.




Figure 1: Schematic overview of the study design




Figure 2: Atherosclerotic plaque (red outline on the left) and inflammatory cell content of the plaques (right graph) in the brachiocephalic arteries of ApoE<sup>-/-</sup> mice

CeO<sub>2</sub> NPs increased serum OVA-specific IgG<sub>1</sub> (see Figure 3a), but not IgE levels in BALB/c mice, suggesting a mild adjuvant effect of CeO<sub>2</sub> NPs. In addition, ZrO<sub>2</sub>-doping related differences in IL-5 (see Figure 3), IL-4 and TNF- $\alpha$  induction in isolated spleen and lymph node cells were observed.




Figure 3: IgG<sub>1</sub> concentration in serum and IL-5 induction in isolated spleen and bronchial lymph node cells in BALB/c mice

Published by

National Institute for Public Health  
and the Environment  
P.O. Box 1 | 3720 BA Bilthoven  
The Netherlands  
www.rivm.nl/en



## Acknowledgements

The work leading to these results has received funding from the European Union's Seventh Framework Programme for research, technology development and demonstration under grant agreement n° 310451 (NanoMILE) and the Netherlands Food and Consumer Product Safety Authority (NVWA).